Page 189 - 2020_02-Haematologica-web

Allogeneic transplantation for -5/5q- AML
or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012;12(5):341- 344.
40. Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicen- ter study. Leukemia. 2012;26(6):1286-1292.
41. Sekeres MA, O'Keefe C, List AF, et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol. 2011;86(1):102- 103.
42. 43.
44.
Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syn- dromes with del(5q) predict disease progres- sion. J Clin Oncol. 2011;29(15):1971-1979. Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 muta- tion in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012;51(12):1086- 1092.
Alsina M, Becker PS, Zhong X, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(8):1183-
1189.
45. Sockel K, Bornhaeuser M, Mischak-
Weissinger E, et al. Lenalidomide mainte- nance after allogeneic HSCT seems to trig- ger acute graft-versus-host disease in patients with high-risk myelodysplastic syn- dromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica. 2012;97(9):e34-e35.
46. Craddock C, Slade D, De Santo C, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019:JCO1800889.
haematologica | 2020; 105(2)
423